RegulatoryOfficial
AIFA adds YESAFILI aflibercept to simplified anti-VEGF monitoring form for four eye indications
🇮🇹 AIFA · Thu 19 Nov 2026
From 19 November 2026, Italian registry users can select YESAFILI (aflibercept) in the simplified multi-drug form for intravitreal anti-VEGF agents, following Determina Pres/1591/2026.
The Italian Medicines Agency (AIFA) has told users of its Monitoring Registries that YESAFILI (aflibercept) can now be selected in the simplified multi-drug monitoring form for intravitreal (IVT) anti-VEGF medicines. The option is available from 19 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
More Regulatory
All →
FDA extends review of Belite Bio's tinlarebant for Stargardt disease to May 2027
Belite Bio, Inc (BLTE) · Fri 20 Nov 2026
FDA publishes new and revised draft product-specific guidances on bioequivalence for generics
🇺🇸 FDA · Fri 20 Nov 2026
Dutch inspectorate posts Biotronik field safety notice on ICD and CRT-D lithium plating
🇳🇱 IGJ · Thu 19 Nov 2026
Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045
🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Thu 19 Nov 2026
China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia
HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026